← board
LIMN
distress 4/10 · elevated risk$0.12-3%today-99% from 52w high
Lead: non-small cell lung cancer · est. market ~$35B (approx, global)
Revenue
pre-revenue
Liquidity
$0M
Runway
—
Shares 1y
+66%
Price & events
-84.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.6%
1D
-19.7%
1W
+7.0%
1M
-40.6%
3M
-84.6%
6M
-98.2%
1Y
—
2Y
—
5Y
-98.5%
All
Overview
- Market Cap
- $5.33M
- Volume
- 490.89K
- 52 Week Range
- $0.10 – $8.71
- Total Shares
- 44.88M
- Float Shares
- 27.11M
- Short %
- 3.05%
- % Held by Insiders
- 28.64%
- % Held by Institutions
- 2.20%
- RVOL
- 0.01x
- Beta
- 0.74
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- early 2027Guided 70%trial initiationsecondaryPhase 1IBA101 · Site activations and patient screening beginSEC 8-K
- second half of 2026Guided 55%regulatory submissionFiled (NDA/BLA)IBA101 · Simultaneous submission to US FDA and Korea MFDSSEC 8-K
- 2025-07-02partnershipMOU to form R&D consortium with Samda Biolab and INNOCS AI for blood-based pancreatic cancer diagnostic.SEC 8-K
- 2025-06-24partnershipIBA101 · Collaboration with Dr. Se-Hoon Lee at Samsung Medical Center for Phase 1 trialSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 44,877,633 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — non-small cell lung cancer
- ABBVAbbVie Inc.$451.1B · D2
- MRKMerck & Co., Inc.$318.8B · D3
- NVSEFNOVARTIS AG$292.0B · D3
- PFEPFIZER INC$142.2B · D3
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- RVMDRevolution Medicines, Inc.$40.3B · D1
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- MAIAMAIA Biotechnology, Inc.$78M · D5
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-22Samda Biolab discloses 5.1% Liminatus Pharma (LIMN) ownership position - Stock Titan
- 2026-07-18Price to earnings forward of Liminatus Pharma, Inc. – BOATS:LIMNW - TradingView
- 2026-07-15Liminatus Pharma (LIMN) Stock Is Trending Overnight — Here’s Why it Spiked Over 30% in After-Hours Session - Sahm
- 2026-07-15Form 13D/A Liminatus Pharma For: 14 July By Investing.com - Investing.com Nigeria
- 2026-07-14Form 4 Liminatus Pharma Inc For: 14 July By Investing.com - Investing.com Nigeria
- 2026-07-14Liminatus Pharma (LIMN) investors Valetudo and Chris Kim report 9.6M-share stake - Stock Titan
- 2026-07-13Form DEF 14A Liminatus Pharma Inc For: 13 July By Investing.com - Investing.com Nigeria
- 2026-07-13Form DEF 14A Liminatus Pharma Inc For: 13 July By Investing.com - Investing.com Canada
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.